• Ander Regueiro, LinkeAxelHeart Center, Leipzig University, Germany, LatibAzeemInterventional Cardiology Unit, Ospedale San Raffaele, Milan, Italy, IhlemannNikolajRighospitalet, Copenhagen, Denmark, UrenaMarinaBichat Hôpital, Paris, France, WaltherThomasKerckhoff Klinik, Nauheim, Germany, HusserOliverDeutsches Herzzentrum, München, Germany, HerrmannHowardCHospital of the University of Pennsylvania, Philadelphia, Nombela-FrancoLuisCardiovascular Institute, Hospital Universitario Clinico San Carlos, Madrid, Spain, CheemaAsimDivision of Cardiology, St. Michaels Hospital, Toronto, Canada, Hervé Le Breton, StorteckyStefanBern University Hospital (on behalf of Swiss Registry Centres), Switzerland, KapadiaSamirCleveland Clinic, BartorelliAntonioLCentro Cardiologico Monzino, Milan, Italy, SinningJan MalteHeart Center Bonn, Germany, Amat-SantosIgnacioHospital Clinico Universitario de Valladolid, Spain, Munoz-GarciaAntonioJDepartment of Cardiology, Hospital Universitario Virgen de la Victoria, Malaga, Spain, LerakisStamatiosEmory University School of Medicine, Atlanta, Gutíerrez-IbanesEnriqueDepartment of Cardiology, Instituto de Investigación Sanitaria Gregorio Marañon, Hospital Gregorio Maranon, Madrid, Spain, Abdel-WahabMohamedHeart Center, Bad Segeberg, Germany, TchetcheDidierClinique Pasteur, Toulouse, France, TestaLucaIRCCS Pol. San Donato, Milan, Italy, EltchaninoffHeleneHôpital Charles Nicolle, University of Rouen, France, LiviUgolinoAOU Santa Maria della Misericordia, Udine, Italy, CastilloJuan CarlosDepartment of Cardiology, Hospital Universitario Reina Sofia, Cordoba, Spain, JilaihawiHasanCedars-Sinai Heart Institute, Los Angeles, WebbJohnGCenter for Heart Valve Innovation, St. Pauls Hospital, Vancouver, Canada, Marco Barbanti, KodaliSusheelColumbia University Medical Center, New York, Fabio de Brito Jr, RibeiroHenriqueBInstituto Nacional Cardiovascular (INCOR), Sao Paulo, Brazil, MiceliAntonioFondazione Toscana G. Monasterio, Massa, Italy, FiorinaClaudiaOspedali Civili di Brescia, Italy, Actis DatoGuglielmo MarioOspedali Mauriziano, Torino, Italy, Francesco Rosato, SerraVicençHospital Vall d’Hebron, Barcelona, Spain, MassonJean-BernardCentre Hospitalier de l’Universite de Montreal, Canada, WijeysunderaHarindraCSunnybrook Health Science Center, Toronto, Canada, Jose Mangione, FerreiraMaria-CristinaHospital Naval Marcilio Dias, Rio de Janeiro, Brazil, Valter Lima, CarvalhoLuisAHospital Pró-cardíaco, Rio de Janeiro, Brazil, AbizaidAlexandreInstituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, Marcos Marino, EstevesViniciusHospital Sao Luiz, Sao Paulo, Brazil, Julio Andrea, Messika-ZeitounDavidBichat Hôpital, Paris, France, HimbertDominiqueBichat Hôpital, Paris, France, KimWon-KeunKerckhoff Klinik, Nauheim, Germany, PellegriniCostanzaDeutsches Herzzentrum, München, Germany, AuffretVincentCentre Hospitalier Universitaire de Rennes, France, NietlispachFabianUniversity Hospital Zurich, Switzerland, PilgrimThomasBern University Hospital (on behalf of Swiss Registry Centres), Switzerland, DurandEricHôpital Charles Nicolle, University of Rouen, France, LiskoJohnEmory University School of Medicine, Atlanta, Raj Makkar, LemosPedroInstituto Nacional Cardiovascular (INCOR), Sao Paulo, Brazil, LeonMartinBColumbia University Medical Center, New York, PuriRishiQuebec Heart & Lung Institute, Laval University, Quebec City, Canada, San RomanAlbertoHospital Clinico Universitario de Valladolid, Spain, VahanianAlecBichat Hôpital, Paris, France, SøndergaardLarsRighospitalet, Copenhagen, Denmark, MangnerNormanHeart Center, Leipzig University, Germany, and Rodés-CabauJosepQuebec Heart & Lung Institute, Laval University, Quebec City, Canada.
• Quebec Heart & Lung Institute, Laval University, Quebec City, Canada
• Circ Cardiovasc Interv. 2019 Nov 1; 12 (11): e007938.

BackgroundNo data exist about the characteristics of infective endocarditis (IE) post-transcatheter aortic valve replacement (TAVR) according to transcatheter valve type. We aimed to determine the incidence, clinical characteristics, and outcomes of patients with IE post-TAVR treated with balloon-expandable valve (BEV) versus self-expanding valve (SEV) systems.MethodsData from the multicenter Infectious Endocarditis After TAVR International Registry was used to compare IE patients with BEV versus SEV.ResultsA total of 245 patients with IE post-TAVR were included (SEV, 47%; BEV, 53%). The timing between TAVR and IE was similar between groups (SEV, 5.5 [1.2-15] months versus BEV, 5.3 [1.7-11.4] months; P=0.89). Enterococcal IE was more frequent in the SEV group (36.5% versus 15.4%; P<0.01), and vegetation location differed according to valve type (stent frame, SEV, 18.6%; BEV, 6.9%; P=0.01; valve leaflet, SEV, 23.9%; BEV, 38.5%; P=0.01). BEV recipients had a higher rate of stroke/systemic embolism (20.0% versus 8.7%, adjusted OR: 2.46, 95% CI: 1.04-5.82, P=0.04). Surgical explant of the transcatheter valve (SEV, 8.7%; BEV, 13.8%; P=0.21), and in-hospital death at the time of IE episode (SEV, 35.6%; BEV, 37.7%; P=0.74) were similar between groups. After a mean follow-up of 13±12 months, 59.1% and 54.6% of the SEV and BEV recipients, respectively, had died (P=0.66).ConclusionsThe characteristics of IE post-TAVR, including microorganism type, vegetation location, and embolic complications but not early or late mortality, differed according to valve type. These results may help to guide the diagnosis and management of IE and inform future research studies in the field.

39 keywords...

hide…